The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus
about
Abrogation of the alternative complement pathway by targeted deletion of murine factor BInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyLectin binding by Giardia lambliaSusceptibility of Campylobacter jejuni to strain-specific bactericidal activity in sera of infected patientsBinding of glycosaminoglycans to the surface of Treponema pallidum and subsequent effects on complement interactions between antigen and antibody.Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci.Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococciImmunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci).Neutrophil Fc receptor participation in phagocytosis of type III group B streptococciStudies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleMannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway.Anchors away: contribution of a glycolipid anchor to bacterial invasion of host cells.Regulation of cell component production by growth rate in the group B Streptococcus.Nonopsonic binding of type III Group B Streptococci to human neutrophils induces interleukin-8 release mediated by the p38 mitogen-activated protein kinase pathway.Decreased protective efficacy of reduced and alkylated human immune serum globulin in experimental infection with Haemophilus influenzae type b.Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B StreptococcusDefinition of a bacterial virulence factor: sialylation of the group B streptococcal capsule.A model of high-affinity antibody binding to type III group B Streptococcus capsular polysaccharideDirect evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency.Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement.Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteinsIsolation and characterization of type IV group B Streptococcus capsular polysaccharide.The Delta subunit of RNA polymerase is required for virulence of Streptococcus agalactiae.Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica.Penicillin-binding protein 1a promotes resistance of group B streptococcus to antimicrobial peptides.Resistance of a Tn4351-generated polysaccharide mutant of Porphyromonas gingivalis to polymorphonuclear leukocyte killingRole of C5a-ase in group B streptococcal resistance to opsonophagocytic killing.Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation.L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci.Opsonization of group B Streptococcus type III: studies using clinical strains and maternal sera.Variations in the opsonic requirements of group B streptococcus type III.Type-specific protection of neonatal rats from lethal group B streptococcal infection by immune sera obtained from human volunteers vaccinated with type III-specific polysaccharide.Quantitation of in vitro opsonic activity of human antibody induced by a vaccine consisting of the type III-specific polysaccharide of group B streptococcus.C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes.The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement PathwaysBactericidal capacity of newborn phagocytes against group B beta-hemolytic streptococci.
P2860
Q28506022-26D722BD-9C7E-46F4-9FE7-CDA3E03FD238Q28972389-CDF0915C-74BF-4946-BE0C-D0E3555A455EQ30450510-4F4609B7-18E8-4F12-B0D0-AABC7431999AQ30451119-3C4B313C-83FB-4C78-B392-CF05C78F5084Q33582586-BC49E62B-B14A-45A9-B55F-8351CB5B522EQ33592329-BECDAEFE-5F93-4DD2-B24B-1F166B3923BEQ33602473-89BB9212-E6CF-49B1-8134-6ABE55D74A1DQ33619365-1FE468E9-3BE6-42E4-9FC6-66D7DAF2DCAEQ33620226-16D793C1-F1B0-4626-8BE2-36BA51279DBFQ33703237-A9413C3F-1DF6-42D8-BF06-BCBDB4CCAC1FQ33752366-C9F2F67E-87B3-4E25-972B-B30A0E652DD6Q33765773-993A7F13-58A2-40BA-8989-DFDD4D37C7A6Q33930886-5A5D4A67-9FC0-4FB2-BBC5-DF2766E1A16BQ33992857-F02DE350-1EF0-485F-85E3-E9C9021E9771Q34003905-1B786661-4D22-4967-BF34-554C1FCDAD26Q34192899-2C8C4806-1A9D-447B-A922-CF5442E3A49AQ34262847-A0913F50-404D-4B68-B41D-FC22AAEECE89Q34320304-1426CB3B-F2A1-4F72-81A2-68FBF7AA0107Q34380379-422CAFA5-687F-45CD-902E-A45EDC584829Q34558270-B061ADBD-AB22-498A-B857-989D821D6E77Q34624357-6F76B170-B83F-498B-A237-83C4589F9EA2Q34628079-ABF1F488-B929-4AFE-B65C-AC438AF615ABQ35093878-AE894F05-C7BC-4C89-A739-E11F491C69CAQ35105538-707ECAAE-B62E-4D3F-8C5E-2E688FC3A75CQ35110746-9A3F77A1-AEDE-4A21-AF70-A7FBE53B73BBQ35111097-83CE673D-C11B-45FD-A677-FB360E4AC402Q35217549-E20737A4-B0CA-4845-A400-286DBA1BE2D1Q35382649-1998BE1B-C617-4843-A306-5109BCFDCC60Q35455618-F68103E3-491C-43F7-A789-D4EC2B362527Q35481196-41D0C0A7-130B-46B3-8A0F-60B5C1689EACQ35766497-E360D51B-E3AC-48FF-8A59-FB066551E1B5Q36018153-C321D2E8-CE1E-4A58-872F-1A8717A7F50AQ36090468-3A1C703F-D5AF-430E-8A57-E0BA5C3E7EDFQ36091664-3F0090C4-42C8-46D5-A9FC-F68CEC9A00EBQ36332961-29FBE34A-A39E-4EDD-BEC2-822FE700AAB4Q36346039-FC088777-7F13-45ED-AA54-77E59110932AQ36349666-5B8417CA-BCFD-434D-B7E0-A26F6F3DFA22Q36350028-708C30A5-444F-4730-92C1-1C256F722461Q36382263-C674D76B-53D5-4CF3-9807-2C2DDA7A75E2Q36430672-7C1CFC23-5CD3-4A5A-B1CE-11B6AE3E46A0
P2860
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年学术文章
@wuu
1980年学术文章
@zh-cn
1980年学术文章
@zh-hans
1980年学术文章
@zh-my
1980年学术文章
@zh-sg
1980年學術文章
@yue
1980年學術文章
@zh
1980年學術文章
@zh-hant
name
The role of specific antibody ...... ype III, group B Streptococcus
@ast
The role of specific antibody ...... ype III, group B Streptococcus
@en
type
label
The role of specific antibody ...... ype III, group B Streptococcus
@ast
The role of specific antibody ...... ype III, group B Streptococcus
@en
prefLabel
The role of specific antibody ...... ype III, group B Streptococcus
@ast
The role of specific antibody ...... ype III, group B Streptococcus
@en
P2093
P2860
P356
P1476
The role of specific antibody ...... ype III, group B Streptococcus
@en
P2093
Edwards MS
Nicholson-Weller A
P2860
P304
P356
10.1084/JEM.151.5.1275
P407
P577
1980-05-01T00:00:00Z